Drugs / D-CIK
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03736330 | Sep 2018 → Oct 2020 | renal cell carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D-CIK | “Autologous dendritic and cytokine-induced killer cells (D-CIK)(1.0-1.5\*10\^10 cells)were incubated with low dose anti-PD-1 antibody” NCT03736330 ↗ |
| Modality | Cell therapy | “immunotherapy with PD-1 blockade (pembrolizumab)-activated autologous DC-CIK cells” PMID 29632736 ↗ Jan 2018 |
| Route | Intravenous | “autologous D-CIK (1.0-1.5\*10\^10 cells) were transferred to patients via intravenous infusion” NCT03736330 ↗ |